Compile Data Set for Download or QSAR
maximum 50k data
Found 359 with Last Name = 'yue' and Initial = 'd'
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388463((1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahy...)
Affinity DataKi:  1.45nMAssay Description:Preparation of Membranes: HEK293 cells stably expressing human CB2 receptor were collected, washed in ice cold PBS, and centrifuged at 48,000×g for 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM532446((1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahy...)
Affinity DataKi:  1.45nMAssay Description:Table D: Radioligand binding assays for human CB2 receptors were performed using two different agonist radioligands, [3H]CP55,940 and [3H]WIN55,212-2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM532448((1aR,5aR)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahy...)
Affinity DataKi:  3.80nMAssay Description:Table D: Radioligand binding assays for human CB2 receptors were performed using two different agonist radioligands, [3H]CP55,940 and [3H]WIN55,212-2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388466((1aR,5aR)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahy...)
Affinity DataKi:  3.80nMAssay Description:Preparation of Membranes: HEK293 cells stably expressing human CB2 receptor were collected, washed in ice cold PBS, and centrifuged at 48,000×g for 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388465((1aR,5aR)-2-(Tetrahydro-pyran-4-ylmethyl)-1a,2,5,5...)
Affinity DataKi:  58.7nMAssay Description:Table D: Radioligand binding assays for human CB2 receptors were performed using two different agonist radioligands, [3H]CP55,940 and [3H]WIN55,212-2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388465((1aR,5aR)-2-(Tetrahydro-pyran-4-ylmethyl)-1a,2,5,5...)
Affinity DataKi:  58.7nMAssay Description:Preparation of Membranes: HEK293 cells stably expressing human CB2 receptor were collected, washed in ice cold PBS, and centrifuged at 48,000×g for 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388461((1aS,5aS)-2-(2,4-Difluoro-phenyl)-1a,2,5,5a-tetrah...)
Affinity DataKi:  97.6nMAssay Description:Table D: Radioligand binding assays for human CB2 receptors were performed using two different agonist radioligands, [3H]CP55,940 and [3H]WIN55,212-2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388461((1aS,5aS)-2-(2,4-Difluoro-phenyl)-1a,2,5,5a-tetrah...)
Affinity DataKi:  97.6nMAssay Description:Preparation of Membranes: HEK293 cells stably expressing human CB2 receptor were collected, washed in ice cold PBS, and centrifuged at 48,000×g for 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388462((1aR,5aR)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahy...)
Affinity DataKi:  97.7nMAssay Description:Preparation of Membranes: HEK293 cells stably expressing human CB2 receptor were collected, washed in ice cold PBS, and centrifuged at 48,000×g for 2...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM532445((1aR,5aR)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahy...)
Affinity DataKi:  97.7nMAssay Description:Table D: Radioligand binding assays for human CB2 receptors were performed using two different agonist radioligands, [3H]CP55,940 and [3H]WIN55,212-2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388463((1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahy...)
Affinity DataKi:  105nMAssay Description:Preparation of Membranes: HEK293 cells stably expressing human CB2 receptor were collected, washed in ice cold PBS, and centrifuged at 48,000×g for 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM532446((1aS,5aS)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahy...)
Affinity DataKi:  105nMAssay Description:Table B: HTRF assay was carried out using a two-step protocol essentially according to the kit manufacturer's instructions, in 20 μL total v...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388461((1aS,5aS)-2-(2,4-Difluoro-phenyl)-1a,2,5,5a-tetrah...)
Affinity DataKi:  207nMAssay Description:Table B: HTRF assay was carried out using a two-step protocol essentially according to the kit manufacturer's instructions, in 20 μL total v...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388461((1aS,5aS)-2-(2,4-Difluoro-phenyl)-1a,2,5,5a-tetrah...)
Affinity DataKi:  207nMAssay Description:Preparation of Membranes: HEK293 cells stably expressing human CB2 receptor were collected, washed in ice cold PBS, and centrifuged at 48,000×g for 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388465((1aR,5aR)-2-(Tetrahydro-pyran-4-ylmethyl)-1a,2,5,5...)
Affinity DataKi:  568nMAssay Description:Table B: HTRF assay was carried out using a two-step protocol essentially according to the kit manufacturer's instructions, in 20 μL total v...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388465((1aR,5aR)-2-(Tetrahydro-pyran-4-ylmethyl)-1a,2,5,5...)
Affinity DataKi:  568nMAssay Description:Preparation of Membranes: HEK293 cells stably expressing human CB2 receptor were collected, washed in ice cold PBS, and centrifuged at 48,000×g for 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM388466((1aR,5aR)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahy...)
Affinity DataKi:  1.20E+3nMAssay Description:Preparation of Membranes: HEK293 cells stably expressing human CB2 receptor were collected, washed in ice cold PBS, and centrifuged at 48,000×g for 2...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM532448((1aR,5aR)-2-(4-Oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahy...)
Affinity DataKi:  1.20E+3nMAssay Description:Table B: HTRF assay was carried out using a two-step protocol essentially according to the kit manufacturer's instructions, in 20 μL total v...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCytochrome P450 2C9(Homo sapiens (Human))
Arena Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50055992(CHEMBL3325842)
Affinity DataIC50:  5.50E+3nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Arena Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50364559(CHEMBL1951032)
Affinity DataIC50:  5.80E+3nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C19(Homo sapiens (Human))
Arena Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50056004(CHEMBL3326667)
Affinity DataIC50:  2.34E+4nMAssay Description:Inhibition of CYP2C19 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Arena Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50056004(CHEMBL3326667)
Affinity DataIC50:  2.57E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Arena Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50106206(CHEMBL3598099)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of human ERG by patch clamp assayMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Arena Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50040961(CHEMBL3354952)
Affinity DataIC50: >3.00E+4nMAssay Description:Inhibition of human ERG channel by patch clamp techniqueMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCytochrome P450 2C9(Homo sapiens (Human))
Arena Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50055993(CHEMBL3325843)
Affinity DataIC50: >5.00E+4nMAssay Description:Inhibition of CYP2C9 (unknown origin)More data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Arena Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50040961(CHEMBL3354952)
Affinity DataIC50: >1.00E+6nMAssay Description:Displacement of [3H]Astemizole from human ERG channelMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Arena Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50106206(CHEMBL3598099)
Affinity DataIC50: >1.00E+6nMAssay Description:Displacement of [3H]-Astemizole from human ERGMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 1(Rattus norvegicus (rat))
Arena Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50040960(CHEMBL3354956)
Affinity DataEC50:  5.00E+3nMAssay Description:Inverse agonist activity at rat recombinant CB1 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040962(CHEMBL3354940)
Affinity DataEC50:  19nMAssay Description:Agonist activity at human recombinant CB1 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040963(CHEMBL3354939)
Affinity DataEC50:  4.40nMAssay Description:Agonist activity at human recombinant CB1 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040964(CHEMBL3354938)
Affinity DataEC50:  2.10nMAssay Description:Agonist activity at human recombinant CB1 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040965(CHEMBL3354937)
Affinity DataEC50:  7.40nMAssay Description:Agonist activity at human recombinant CB1 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040966(CHEMBL3354936)
Affinity DataEC50:  51nMAssay Description:Agonist activity at human recombinant CB1 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 1(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040967(CHEMBL3354935)
Affinity DataEC50:  86nMAssay Description:Agonist activity at human recombinant CB1 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040968(CHEMBL3352843)
Affinity DataEC50:  420nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040969(CHEMBL3354976)
Affinity DataEC50:  25nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040970(CHEMBL3354975 | US11214548, Compound 269)
Affinity DataEC50:  809nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040971(CHEMBL3354974)
Affinity DataEC50:  42nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040972(CHEMBL3354973)
Affinity DataEC50:  15nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040973(CHEMBL3354972)
Affinity DataEC50:  2.30E+4nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040974(CHEMBL3354971)
Affinity DataEC50:  0.900nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040975(CHEMBL3354970)
Affinity DataEC50:  25nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040976(CHEMBL3354969)
Affinity DataEC50:  7.40nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040977(CHEMBL3354968)
Affinity DataEC50:  19nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040978(CHEMBL3354967)
Affinity DataEC50:  101nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040979(CHEMBL3354966 | US11214548, Compound 408)
Affinity DataEC50:  76nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040980(CHEMBL3354965)
Affinity DataEC50:  39nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040981(CHEMBL3354964)
Affinity DataEC50:  25nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040982(CHEMBL3354963)
Affinity DataEC50:  3nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
TargetCannabinoid receptor 2(Homo sapiens (Human))
Arena Pharmaceuticals

US Patent
LigandPNGBDBM50040983(CHEMBL3354962)
Affinity DataEC50:  7.20nMAssay Description:Agonist activity at human recombinant CB2 receptor expressed in CHOK1 cells assessed as cAMP accumulation by HTRF methodMore data for this Ligand-Target Pair
In DepthDetails ArticlePubMed
Displayed 1 to 50 (of 359 total ) | Next | Last >>
Jump to: